Vibramycin

Phase 3Small molecule

WWarner Chilcott

Vibramycin is one of 48 small molecule programs targeting Mycosis Fungoides. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mycosis FungoidesActive, not recruiting

Mycosis FungoidesPhase 3

Active, not recruiting

Competition

Competitive Landscape

56 competitors in Mycosis Fungoides

#DrugCompanyPhaseTrials

Arranon

Istodax

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Rayos

Decadron

AAspen Global Incorporated

Approved

—6

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Adcetris

5 8

Keytruda

Merck & Co.

Phase 2

4 9

Trexall

Alnylam Pharmaceuticals

Phase 2

1 10

Fludara

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mycosis Fungoides1 trial

Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides

Unknown status·—·Phase 3·NCT03454945·30 enrolled

Treatment1 trial

Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin

Completed·WWarner Chilcott·Phase 3·NCT01113931·495 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Vibramycin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vibramycin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vibramycin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Warner Chilcott company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: WWarner Chilcott

Vibramycin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mycosis Fungoides1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News